About this data
What it is
When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
Who files it
The insider, usually through the company, within two business days of the trade.
How current
We collect new filings throughout the day on SEC business days.
Worth knowing
Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.

All of this comes from public filings.

Open-market trades per day, last 30 days

05001,000Oct 17 · Purchases: 0Oct 17 · Sales: 0Oct 17Oct 18 · Purchases: 0Oct 18 · Sales: 0Oct 19 · Purchases: 29Oct 19 · Sales: 159Oct 20 · Purchases: 45Oct 20 · Sales: 209Oct 21 · Purchases: 38Oct 21 · Sales: 183Oct 21Oct 22 · Purchases: 50Oct 22 · Sales: 130Oct 23 · Purchases: 77Oct 23 · Sales: 126Oct 24 · Purchases: 1Oct 24 · Sales: 0Oct 25 · Purchases: 0Oct 25 · Sales: 0Oct 25Oct 26 · Purchases: 60Oct 26 · Sales: 171Oct 27 · Purchases: 27Oct 27 · Sales: 217Oct 28 · Purchases: 44Oct 28 · Sales: 135Oct 29 · Purchases: 35Oct 29 · Sales: 199Oct 29Oct 30 · Purchases: 68Oct 30 · Sales: 270Oct 31 · Purchases: 3Oct 31 · Sales: 0Nov 1 · Purchases: 2Nov 1 · Sales: 0Nov 2 · Purchases: 79Nov 2 · Sales: 826Nov 2Nov 3 · Purchases: 66Nov 3 · Sales: 337Nov 4 · Purchases: 67Nov 4 · Sales: 535Nov 5 · Purchases: 108Nov 5 · Sales: 458Nov 6 · Purchases: 137Nov 6 · Sales: 390Nov 6Nov 7 · Purchases: 0Nov 7 · Sales: 0Nov 8 · Purchases: 0Nov 8 · Sales: 0Nov 9 · Purchases: 110Nov 9 · Sales: 457Nov 10 · Purchases: 97Nov 10 · Sales: 406Nov 10Nov 11 · Purchases: 98Nov 11 · Sales: 330Nov 12 · Purchases: 54Nov 12 · Sales: 167Nov 13 · Purchases: 23Nov 13 · Sales: 28Nov 14 · Purchases: 0Nov 14 · Sales: 0Nov 14Nov 15 · Purchases: 0Nov 15 · Sales: 0
05001,000Oct 17 · Purchases: 0Oct 17 · Sales: 0Oct 17Oct 18 · Purchases: 0Oct 18 · Sales: 0Oct 19 · Purchases: 29Oct 19 · Sales: 159Oct 20 · Purchases: 45Oct 20 · Sales: 209Oct 21 · Purchases: 38Oct 21 · Sales: 183Oct 21Oct 22 · Purchases: 50Oct 22 · Sales: 130Oct 23 · Purchases: 77Oct 23 · Sales: 126Oct 24 · Purchases: 1Oct 24 · Sales: 0Oct 25 · Purchases: 0Oct 25 · Sales: 0Oct 25Oct 26 · Purchases: 60Oct 26 · Sales: 171Oct 27 · Purchases: 27Oct 27 · Sales: 217Oct 28 · Purchases: 44Oct 28 · Sales: 135Oct 29 · Purchases: 35Oct 29 · Sales: 199Oct 29Oct 30 · Purchases: 68Oct 30 · Sales: 270Oct 31 · Purchases: 3Oct 31 · Sales: 0Nov 1 · Purchases: 2Nov 1 · Sales: 0Nov 2 · Purchases: 79Nov 2 · Sales: 826Nov 2Nov 3 · Purchases: 66Nov 3 · Sales: 337Nov 4 · Purchases: 67Nov 4 · Sales: 535Nov 5 · Purchases: 108Nov 5 · Sales: 458Nov 6 · Purchases: 137Nov 6 · Sales: 390Nov 6Nov 7 · Purchases: 0Nov 7 · Sales: 0Nov 8 · Purchases: 0Nov 8 · Sales: 0Nov 9 · Purchases: 110Nov 9 · Sales: 457Nov 10 · Purchases: 97Nov 10 · Sales: 406Nov 10Nov 11 · Purchases: 98Nov 11 · Sales: 330Nov 12 · Purchases: 54Nov 12 · Sales: 167Nov 13 · Purchases: 23Nov 13 · Sales: 28Nov 14 · Purchases: 0Nov 14 · Sales: 0Nov 14Nov 15 · Purchases: 0Nov 15 · Sales: 0

Purchases Sales

By trade date. Insiders have two business days to file, so the most recent days fill in later.

Latest open-market insider trades

Reset

Showing: ticker KLRS

Latest open-market insider trades
TradedInsiderCompanyTypeSharesPriceValueFiling
May 20, 2026Samsara BioCapital, L.P.
10% owner
KLRS
Kalaris Therapeutics, Inc.
Buy244,300$4.83$1.2M BuyForm 4 ↗
Mar 20, 2026Brett R. Hagen
Chief Accounting Officer
KLRS
Kalaris Therapeutics, Inc.
Sale1,915$6.72$12.9K SaleForm 4 ↗
Dec 18, 2025Samsara Opportunity Fund, L.P.
10% owner
KLRS
Kalaris Therapeutics, Inc.
Buy479,847$10.42$5.0M BuyForm 4 ↗
Mar 26, 2025Brett R. Hagen
Chief Accounting Officer
KLRS
Kalaris Therapeutics, Inc.
Sale907$8.97$8,136 SaleForm 4 ↗
Feb 21, 2025Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale303$10.08$3,054 SaleForm 4 ↗
Feb 21, 2025Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale96$10.08$968 SaleForm 4 ↗
Feb 21, 2025Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale106$10.08$1,068 SaleForm 4 ↗
Jan 23, 2025Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale5$9.94$49.7 SaleForm 4 ↗
Jan 23, 2025Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale47$9.45$444 SaleForm 4 ↗
Jan 23, 2025Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale4$9.94$39.76 SaleForm 4 ↗
Jan 23, 2025Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale32$9.45$302 SaleForm 4 ↗
Jan 23, 2025Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale13$9.94$129 SaleForm 4 ↗
Jan 23, 2025Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale116$9.45$1,096 SaleForm 4 ↗
Jan 10, 2025Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale409$0.44$180 SaleForm 4 ↗
Jan 10, 2025Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale332$0.44$146 SaleForm 4 ↗
Jan 10, 2025Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale979$0.44$431 SaleForm 4 ↗
Nov 19, 2024Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale554$0.55$305 SaleForm 4 ↗
Nov 19, 2024Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale3,186$0.55$1,752 SaleForm 4 ↗
Nov 19, 2024Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale432$0.55$238 SaleForm 4 ↗
Nov 19, 2024Diana Brainard
Chief Executive Officer, Director
ALVR
Kalaris Therapeutics, Inc.
Sale8,706$0.55$4,788 SaleForm 4 ↗
Nov 5, 2024Diana Brainard
Chief Executive Officer, Director
ALVR
Kalaris Therapeutics, Inc.
Sale10,609$0.86$9,124 SaleForm 4 ↗
Nov 5, 2024Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale2,272$0.86$1,954 SaleForm 4 ↗
Nov 5, 2024Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale1,655$0.86$1,423 SaleForm 4 ↗
Nov 5, 2024Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale5,136$0.86$4,417 SaleForm 4 ↗
Oct 22, 2024Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale1,882$0.77$1,449 SaleForm 4 ↗
Oct 22, 2024Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale486$0.77$374 SaleForm 4 ↗
Oct 22, 2024Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale766$0.77$590 SaleForm 4 ↗
Oct 21, 2024Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale1,546$0.78$1,206 SaleForm 4 ↗
Oct 21, 2024Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale479$0.78$374 SaleForm 4 ↗
Oct 21, 2024Diana Brainard
Chief Executive Officer, Director
ALVR
Kalaris Therapeutics, Inc.
Sale9,752$0.78$7,607 SaleForm 4 ↗
Oct 21, 2024Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale635$0.78$495 SaleForm 4 ↗
Oct 3, 2024Vikas Sinha
See Remarks, Director, 10% owner
ALVR
Kalaris Therapeutics, Inc.
Sale940$0.81$761 SaleForm 4 ↗
Oct 3, 2024Edward Miller
General Counsel
ALVR
Kalaris Therapeutics, Inc.
Sale377$0.81$305 SaleForm 4 ↗
Oct 3, 2024Diana Brainard
Chief Executive Officer, Director
ALVR
Kalaris Therapeutics, Inc.
Sale1,493$0.81$1,209 SaleForm 4 ↗
Oct 3, 2024Brett R. Hagen
Chief Accounting Officer
ALVR
Kalaris Therapeutics, Inc.
Sale301$0.81$244 SaleForm 4 ↗

35 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 7:16 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances